Immunomodulation is a privately-held biopharmaceutical company focused on developing breakthrough therapies to modulate immune responses in multiple high value oncology and serious infectious disease indications.
Our lead program, IMM-010 (annexin V) is in preclinical development for the treatment of solid tumors and certain viruses and has the potential for additional pipeline expansion opportunities. IMM-010 binds to phosphatidylserine (PS) on tumor cells and infective organisms. It has been demonstrated to be effective in generating immune responses and has shown both tumor size reduction and anti-infective effects in animal models of diseases.
We are working in collaboration with a network of leading institutions, including Stanford University School of Medicine and the University of South Alabama to drive the execution of our development plan. Based on previous clinical experience of the Company’s founders with annexin V as an imaging agent, we expect to file an IND for IMM-010 in less than 18 months.